Nivolumab Plus Ipilimumab for Advanced Lung Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 15, 2021

Media advisory: The full study is linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.2209?guestAccessKey=19094b6b-dc8e-4aa5-aa5e-9f8f7587be76&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071521

 

Visual Abstract

 

Authors: Scott N. Gettinger, M.D., of the Yale Cancer Center in New Haven, Connecticut, is the corresponding author.

(doi:10.1001/jamaoncol.2021.2209)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.